Silence Therapeutics Plc American Depository Share
SLN Real Time Price USDRecent trades of SLN by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by SLN's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Products and compositions Sep. 10, 2024
-
Patent Title: Nucleic acids for inhibiting expression of tmprss6 and iron chelators Sep. 03, 2024
-
Patent Title: Nucleic acids for inhibiting expression of lpa in a cell Aug. 06, 2024
-
Patent Title: Products and compositions May. 21, 2024
-
Patent Title: Nucleic acid linked to a trivalent glycoconjugate Feb. 27, 2024
-
Patent Title: Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages Jan. 16, 2024
-
Patent Title: Nucleic acids for inhibiting expression of c3 in a cell Sep. 12, 2023
-
Patent Title: Interfering rna molecules Feb. 14, 2023
-
Patent Title: Sirnas with vinylphosphonate at the 5′ end of the antisense strand Jan. 24, 2023
-
Patent Title: Nucleic acids for inhibiting expression of lpa in a cell Nov. 15, 2022
-
Patent Title: Products and compositions Aug. 16, 2022
-
Patent Title: Nucleic acids for inhibiting expression of lpa in a cell May. 03, 2022
-
Patent Title: Further novel oligonucleotide-ligand conjugates Apr. 12, 2022
-
Patent Title: Products and compositions Nov. 16, 2021
-
Patent Title: Products and compositions May. 25, 2021
-
Patent Title: Nucleic acid linked to a trivalent glycoconjugate Feb. 09, 2021
-
Patent Title: Interfering rna molecules Sep. 15, 2020
-
Patent Title: Interfering rna molecules Jun. 25, 2019
-
Patent Title: Interfering rna molecules Jun. 18, 2019
-
Patent Title: Interfering rna molecules Apr. 23, 2019
-
Patent Title: Interfering rna molecules Oct. 17, 2017
-
Patent Title: Interfering rna molecules Oct. 17, 2017
-
Patent Title: Interfering rna molecules Oct. 10, 2017
-
Patent Title: Interfering rna molecules Sep. 12, 2017
-
Patent Title: Interfering rna molecules Jul. 04, 2017
-
Patent Title: Lipids, lipid complexes and use thereof Nov. 08, 2016
-
Patent Title: Means for inhibiting the expression of ang2 Oct. 04, 2016
-
Patent Title: Coated lipid complexes and their use Jul. 12, 2016
-
Patent Title: Interfering rna molecules Dec. 29, 2015
-
Patent Title: Use of vegfr1 as a biomarker Sep. 15, 2015
-
Patent Title: Lipids, lipid complexes and use thereof Sep. 08, 2015
-
Patent Title: Further use of protein kinase n beta Jul. 14, 2015
-
Patent Title: Interfering rna molecules Jan. 13, 2015
-
Patent Title: Coated lipid complexes and their use Oct. 07, 2014
-
Patent Title: Means for inhibiting the expression of ang2 Sep. 09, 2014
-
Patent Title: Lipids, lipid complexes and use thereof May. 27, 2014
-
Patent Title: Means for inhibiting the expression of orc-1 May. 13, 2014
-
Patent Title: Lipids, lipid complexes and use thereof Jan. 22, 2013
-
Patent Title: Interfering rna molecules Dec. 04, 2012
-
Patent Title: Means for inhibiting the expression of protein kinase 3 Jul. 31, 2012
-
Patent Title: Lipids, lipid complexes and use thereof Sep. 13, 2011
-
Patent Title: Interfering rna molecules Feb. 22, 2011
-
Patent Title: Further use of protein kinase n beta May. 11, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of SLN in WallStreetBets Daily Discussion
Recent insights relating to SLN
Recent picks made for SLN stock on CNBC
ETFs with the largest estimated holdings in SLN
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view SLN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.